
Five Prime Therapeutics, Inc. FPRX
Country |
|
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
36.8 M |
Market Cap[1] |
$ 1.77 B |
EBITDA (LTM) |
$ 17.3 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 119.1 | 2.14 % | $ 7.74 B | Nasdaq Global Market,SPB | ||
|
iTeos Therapeutics
ITOS
|
- | - | $ 411 M | Nasdaq Global Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 2.76 | -8.35 % | $ 36.8 M | Nasdaq Global Market | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | ||
|
Cullinan Management
CGEM
|
$ 9.01 | -2.86 % | $ 543 M | Nasdaq Global Select Market | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 54.13 | 2.46 % | $ 151 M | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | ||
|
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | ||
|
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market | ||
|
Annovis Bio
ANVS
|
$ 0.81 | 9.63 % | $ 16.6 M | NYSE American | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
X4 Pharmaceuticals
XFOR
|
$ 3.02 | -2.27 % | $ 128 M | Nasdaq Capital Market | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.52 | -0.62 % | $ 5.75 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
Evogene Ltd.
EVGN
|
$ 0.36 | 5.82 % | $ 2.83 M | Nasdaq Global Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 4.44 | 6.99 % | $ 1.97 M | Nasdaq Capital Market | ||
|
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | ||
|
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | ||
|
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market | ||
|
Gilead Sciences
GILD
|
$ 168.96 | -0.77 % | $ 210 B | Nasdaq Global Select Market,SPB | ||
|
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | ||
|
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | ||
|
Cocrystal Pharma
COCP
|
$ 0.96 | -4.95 % | $ 10.8 M | Nasdaq Capital Market | ||
|
Fortress Biotech
FBIO
|
$ 1.89 | 3.85 % | $ 52.7 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Longeveron
LGVN
|
$ 1.93 | -8.53 % | $ 33.9 B | Nasdaq Global Select Market | ||
|
Mersana Therapeutics
MRSN
|
- | - | $ 3.56 B | Nasdaq Global Select Market | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 6.51 | 14.22 % | $ 438 B | Nasdaq Capital Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.